Detailed Information on Publication Record
2023
Proteogenomic Classification of Triple-Negative Breast Cancer for Prognosis and Targeted Therapy
HRACHOVINOVÁ, Šárka, Pavla BOUCHALOVÁ, Petr LAPČÍK, David POTĚŠIL, Kateřina JURÁSKOVÁ et. al.Basic information
Original name
Proteogenomic Classification of Triple-Negative Breast Cancer for Prognosis and Targeted Therapy
Name in Czech
Proteogenomická klasifikace trojitě-negativních karcinomů prsu pro stanovení prognózy a cílené terapie
Authors
HRACHOVINOVÁ, Šárka (203 Czech Republic, belonging to the institution), Pavla BOUCHALOVÁ (203 Czech Republic, belonging to the institution), Petr LAPČÍK (203 Czech Republic, belonging to the institution), David POTĚŠIL (203 Czech Republic, belonging to the institution), Kateřina JURÁSKOVÁ (203 Czech Republic, belonging to the institution), Vojtěch BYSTRÝ (203 Czech Republic, belonging to the institution), Boris TICHÝ (203 Czech Republic, belonging to the institution), Rudolf NENUTIL (203 Czech Republic, belonging to the institution), Roman HRSTKA (203 Czech Republic, belonging to the institution) and Pavel BOUCHAL (203 Czech Republic, belonging to the institution)
Edition
Abstract Book of Doctoral conference 2023, Brno, CZ, 1.6.2023, 2023
Other information
Language
English
Type of outcome
Konferenční abstrakt
Field of Study
10608 Biochemistry and molecular biology
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
RIV identification code
RIV/00216224:14310/23:00132896
Organization unit
Faculty of Science
Keywords in English
triple-negative breast cancer; classification; proteomics; genomics; transcriptomics; subtypes
Změněno: 5/4/2024 10:00, Mgr. Tereza Miškechová
Abstract
V originále
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterised by the absence of estrogen, progesterone, and HER2 receptors. This subtype accounts for approximately 15% of all breast cancers and mainly affects premenopausal women under the age of 40. Unfortunately, TNBC has a very poor prognosis, with chemotherapy as the typical primary treatment due to the lack of targetable receptors. Currently, TNBC is classified based on histological features and molecular profiling. The widely accepted classifications by Lehmann (2011 and 2016) and Burstein (2015) utilise gene expression profiling data and suggest ~four TNBC groups with different characteristics. However, we hypothesise that next-generation proteomics should provide a more relevant classification of the TNBC phenotype, as proteins are the true molecular effectors in cells. The unique and well-characterised set of 114 TNBC fresh frozen tissues from the Masaryk Memorial Cancer Institute was processed for this project. Whole exome sequencing (WES), RNA sequencing on Illumina NovaSeq, and proteomics analysis in DIA-MS mode on timsTOF Pro were performed, resulting in a set of 101 samples with high-quality genomics, transcriptomics, and proteomics data. We will classify these samples based on RNA and protein profiles and will use WES data to identify somatic variants in coding genomic regions responsible for this proteogenomic classification. The key milestone of this project is to identify new potential therapeutic targets that could be potentially utilised to improve TNBC therapy.
Links
| LM2018127, research and development project |
| ||
| LX22NPO5102, research and development project |
| ||
| MUNI/A/1313/2022, interní kód MU |
| ||
| NU22-08-00230, research and development project |
|